Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 28

1.

Circulating follicular helper T cells exhibit reduced ICOS expression and impaired function in narcolepsy type 1 patients.

Nguyen XH, Dauvilliers Y, Quériault C, Perals C, Romieu-Mourez R, Paulet PE, Bernard-Valnet R, Fazilleau N, Liblau R.

J Autoimmun. 2018 Nov;94:134-142. doi: 10.1016/j.jaut.2018.07.021. Epub 2018 Aug 6.

PMID:
30104107
2.

Human mesenchymal stromal cells transiently increase cytokine production by activated T cells before suppressing T-cell proliferation: effect of interferon-γ and tumor necrosis factor-α stimulation.

Cuerquis J, Romieu-Mourez R, François M, Routy JP, Young YK, Zhao J, Eliopoulos N.

Cytotherapy. 2014 Feb;16(2):191-202. doi: 10.1016/j.jcyt.2013.11.008.

PMID:
24438900
3.

Proteomic profiling of a mouse model for ovarian granulosa cell tumor identifies VCP as a highly sensitive serum tumor marker in several human cancers.

Laguë MN, Romieu-Mourez R, Bonneil É, Boyer A, Pouletty N, Mes-Masson AM, Thibault P, Nadeau MÈ, Boerboom D.

PLoS One. 2012;7(8):e42470. doi: 10.1371/journal.pone.0042470. Epub 2012 Aug 1.

4.

The immune plasticity of mesenchymal stromal cells from mice and men: concordances and discrepancies.

Romieu-Mourez R, Coutu DL, Galipeau J.

Front Biosci (Elite Ed). 2012 Jan 1;4:824-37. Review.

PMID:
22201917
5.

Cryopreserved mesenchymal stromal cells display impaired immunosuppressive properties as a result of heat-shock response and impaired interferon-γ licensing.

François M, Copland IB, Yuan S, Romieu-Mourez R, Waller EK, Galipeau J.

Cytotherapy. 2012 Feb;14(2):147-52. doi: 10.3109/14653249.2011.623691. Epub 2011 Oct 27.

6.

Human MSC suppression correlates with cytokine induction of indoleamine 2,3-dioxygenase and bystander M2 macrophage differentiation.

François M, Romieu-Mourez R, Li M, Galipeau J.

Mol Ther. 2012 Jan;20(1):187-95. doi: 10.1038/mt.2011.189. Epub 2011 Sep 20.

7.

A dendritic cell population generated by a fusion of GM-CSF and IL-21 induces tumor-antigen-specific immunity.

Williams P, Bouchentouf M, Rafei M, Romieu-Mourez R, Hsieh J, Boivin MN, Yuan S, Forner KA, Birman E, Galipeau J.

J Immunol. 2010 Dec 15;185(12):7358-66. doi: 10.4049/jimmunol.1002201. Epub 2010 Nov 12.

8.

Mesenchymal stromal cells expressing ErbB-2/neu elicit protective antibreast tumor immunity in vivo, which is paradoxically suppressed by IFN-gamma and tumor necrosis factor-alpha priming.

Romieu-Mourez R, François M, Abate A, Boivin MN, Birman E, Bailey D, Bramson JL, Forner K, Young YK, Medin JA, Galipeau J.

Cancer Res. 2010 Oct 15;70(20):7742-7. doi: 10.1158/0008-5472.CAN-10-0296. Epub 2010 Oct 5.

9.

Mesenchymal stromal cells cross-present soluble exogenous antigens as part of their antigen-presenting cell properties.

François M, Romieu-Mourez R, Stock-Martineau S, Boivin MN, Bramson JL, Galipeau J.

Blood. 2009 Sep 24;114(13):2632-8. doi: 10.1182/blood-2009-02-207795. Epub 2009 Aug 4.

PMID:
19654411
10.

Cytokine modulation of TLR expression and activation in mesenchymal stromal cells leads to a proinflammatory phenotype.

Romieu-Mourez R, François M, Boivin MN, Bouchentouf M, Spaner DE, Galipeau J.

J Immunol. 2009 Jun 15;182(12):7963-73. doi: 10.4049/jimmunol.0803864.

11.

Transcriptional re-programming of primary macrophages reveals distinct apoptotic and anti-tumoral functions of IRF-3 and IRF-7.

Goubau D, Romieu-Mourez R, Solis M, Hernandez E, Mesplède T, Lin R, Leaman D, Hiscott J.

Eur J Immunol. 2009 Feb;39(2):527-40. doi: 10.1002/eji.200838832.

12.
13.

Involvement of TBK1 and IKKepsilon in lipopolysaccharide-induced activation of the interferon response in primary human macrophages.

Solis M, Romieu-Mourez R, Goubau D, Grandvaux N, Mesplede T, Julkunen I, Nardin A, Salcedo M, Hiscott J.

Eur J Immunol. 2007 Feb;37(2):528-39.

14.

Distinct roles for IFN regulatory factor (IRF)-3 and IRF-7 in the activation of antitumor properties of human macrophages.

Romieu-Mourez R, Solis M, Nardin A, Goubau D, Baron-Bodo V, Lin R, Massie B, Salcedo M, Hiscott J.

Cancer Res. 2006 Nov 1;66(21):10576-85.

15.

Induction of IRF-3 and IRF-7 phosphorylation following activation of the RIG-I pathway.

Paz S, Sun Q, Nakhaei P, Romieu-Mourez R, Goubau D, Julkunen I, Lin R, Hiscott J.

Cell Mol Biol (Noisy-le-grand). 2006 May 15;52(1):17-28.

PMID:
16914100
16.

Distinct functions of IRF-3 and IRF-7 in IFN-alpha gene regulation and control of anti-tumor activity in primary macrophages.

Solis M, Goubau D, Romieu-Mourez R, Genin P, Civas A, Hiscott J.

Biochem Pharmacol. 2006 Nov 30;72(11):1469-76. Epub 2006 Jul 17. Review.

PMID:
16846591
17.

Inducible IkappaB kinase/IkappaB kinase epsilon expression is induced by CK2 and promotes aberrant nuclear factor-kappaB activation in breast cancer cells.

Eddy SF, Guo S, Demicco EG, Romieu-Mourez R, Landesman-Bollag E, Seldin DC, Sonenshein GE.

Cancer Res. 2005 Dec 15;65(24):11375-83.

18.

RelB/p52 NF-kappaB complexes rescue an early delay in mammary gland development in transgenic mice with targeted superrepressor IkappaB-alpha expression and promote carcinogenesis of the mammary gland.

Demicco EG, Kavanagh KT, Romieu-Mourez R, Wang X, Shin SR, Landesman-Bollag E, Seldin DC, Sonenshein GE.

Mol Cell Biol. 2005 Nov;25(22):10136-47.

19.

Inhibition of CK2 activity by TGF-beta1 promotes IkappaB-alpha protein stabilization and apoptosis of immortalized hepatocytes.

Cavin LG, Romieu-Mourez R, Panta GR, Sun J, Factor VM, Thorgeirsson SS, Sonenshein GE, Arsura M.

Hepatology. 2003 Dec;38(6):1540-51.

PMID:
14647065
20.

Mouse mammary tumor virus c-rel transgenic mice develop mammary tumors.

Romieu-Mourez R, Kim DW, Shin SM, Demicco EG, Landesman-Bollag E, Seldin DC, Cardiff RD, Sonenshein GE.

Mol Cell Biol. 2003 Aug;23(16):5738-54.

21.

Protein kinase CK2 promotes aberrant activation of nuclear factor-kappaB, transformed phenotype, and survival of breast cancer cells.

Romieu-Mourez R, Landesman-Bollag E, Seldin DC, Sonenshein GE.

Cancer Res. 2002 Nov 15;62(22):6770-8.

22.

Protein kinase CK2: signaling and tumorigenesis in the mammary gland.

Landesman-Bollag E, Song DH, Romieu-Mourez R, Sussman DJ, Cardiff RD, Sonenshein GE, Seldin DC.

Mol Cell Biochem. 2001 Nov;227(1-2):153-65.

PMID:
11827167
23.

Protein kinase CK2 in mammary gland tumorigenesis.

Landesman-Bollag E, Romieu-Mourez R, Song DH, Sonenshein GE, Cardiff RD, Seldin DC.

Oncogene. 2001 May 31;20(25):3247-57.

24.

Roles of IKK kinases and protein kinase CK2 in activation of nuclear factor-kappaB in breast cancer.

Romieu-Mourez R, Landesman-Bollag E, Seldin DC, Traish AM, Mercurio F, Sonenshein GE.

Cancer Res. 2001 May 1;61(9):3810-8.

25.

Repression of transcription of the p27(Kip1) cyclin-dependent kinase inhibitor gene by c-Myc.

Yang W, Shen J, Wu M, Arsura M, FitzGerald M, Suldan Z, Kim DW, Hofmann CS, Pianetti S, Romieu-Mourez R, Freedman LP, Sonenshein GE.

Oncogene. 2001 Mar 29;20(14):1688-702.

26.
27.

The RelA NF-kappaB subunit and the aryl hydrocarbon receptor (AhR) cooperate to transactivate the c-myc promoter in mammary cells.

Kim DW, Gazourian L, Quadri SA, Romieu-Mourez R, Sherr DH, Sonenshein GE.

Oncogene. 2000 Nov 16;19(48):5498-506.

28.

Activation of NF-kappaB/Rel occurs early during neoplastic transformation of mammary cells.

Kim DW, Sovak MA, Zanieski G, Nonet G, Romieu-Mourez R, Lau AW, Hafer LJ, Yaswen P, Stampfer M, Rogers AE, Russo J, Sonenshein GE.

Carcinogenesis. 2000 May;21(5):871-9.

PMID:
10783306

Supplemental Content

Loading ...
Support Center